Orion Oyj (HEL:ORNBV)

Market Cap	8.96B
Revenue (ttm)	1.68B
Net Income (ttm)	378.00M
Shares Out	140.69M
EPS (ttm)	2.69
PE Ratio	23.71
Forward PE	18.83
Dividend	1.64 (2.57%)
Ex-Dividend Date	Oct 15, 2025

Volume	275,676
Average Volume	176,214
Open	63.75
Previous Close	65.00
Day's Range	62.85 - 64.35
52-Week Range	41.39 - 72.05
Beta	0.35
RSI	35.91
Earnings Date	Oct 28, 2025

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 3,880
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: ORNBV

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.